EGFR and HER2/NEU immunoexpression in ovarian neoplasms in Bundelkhand Region
Keywords:
IHC, HER2/neu, EGFRAbstract
Introduction: Ovarian Cancers account for the greatest number of deaths from malignancies of female genital tract and it is the fifth leading cause of cancer fatalities in women. Surface epithelial tumours are the most common, followed by germ cell tumours. Objective: To analyse the expression of EGFR and HER 2neu using Immunohistochemisty in different Ovarian tumours with special reference to surface Epithelial tumours. Material and Methods: 52 cases of different ovarian tumours were studied. Cases included total abdominal hysterectomy with bilateral saphingoophorectomy, oophorectomy, and cystectomy specimens. Expression of EGFR (ErbB1) and HER2-neu (ErbB2) was determined by immunohistochemical reactions performed with the Super SensitiveTM IHC Detection system by the BiogenixTM. Tests were performed according to the instructions of each kit. Results: The mean age of presentation for epithelial tumours was found to be 42.48 years. For malignant epithelial tumours mean age of presentation was found to be 51.1 years. EGFR positivity was found in 28.57 % of surface epithelial ovarians tumours, and HER2/neu positivity was seen in 20% of surface epithelial ovarian tumours. As far as malignant serous papillary adenocarcinoma is concerned, we found 33.3% positivity for HER2/neu and 50% positivity for EGFR.
Downloads
References
Rosai and Ackerman’s Surgical Pathology. Tenth Edition.
WHO classification of female reproductive organs.
Study of 'patterns of care' of ovarian cancer patients in a specialized cancer institute in Kolkata, eastern India P Basu1, P De, S Mandal, K Ray, J Biswas. Robbins &Cotran Pathologic Basis of Disease. 8th Edition.
Spectrum of Epithelial Ovarian tumours with HER 2/neu Expression by the cancinomas as among patients admitted in a tertiary care hospital in Eastern india. Manisha Sarkar, TulikaJhan, TusharKanti Das, Vidyasagar Sau, SuklaMitra, Kuntal Roy.
Buller RE, Anderson B, Connor JP, Robinson R. Familial ovarian cancer. Gynecol Oncol.1993;51(2):160. DOI: https://doi.org/10.1006/gyno.1993.1265
Verri E, Guglielmini P, Puntoni M, et al. HER2/neuoncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance.
A Comparative Study of HER-2/neu Oncogene in Benign and Malignant Ovarian Tumors Sapna Goel , Manju Mehra, Ajay Yadav , Mahak Sharma.
Rubin SC, Finstad CL, Wong GY, et al. Prognostic significance of HER-2/ neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol. 1993 DOI: https://doi.org/10.1016/S0002-9378(12)90907-2
Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Psyrri A1, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA.
Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?Demir L1, Yigit S, Sadullahoglu C, Akyol M, Cokmert S, Kucukzeybek Y, Alacacioglu A, Cakalagaoglu F, Tarhan MO
Borderline Brenner tumor of the ovary: a case report with immunohistochemical and molecular study.De Cecio R1, Cantile M2, Collina F3, Marra L4, Santonastaso C5, Scaffa C6, Botti G7, Losito NS8
The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinomaSkirnisdóttir I1, Sorbe B, Seidal T.
Expression of EGFR, HER-2/neu and KIT in germ cell tumours.Durán I1, García-Velasco A, Ballestín C, García E, Martínez-Tello F, Pond GR, García-Carbonero R, Cortés-Funés H, Paz-Ares L.
The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Skirnisdóttir I, Sorbe B, Seidal T
Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Høgdall EV1, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Nørgaard-Pedersen B, Høgdall CK.
Nielsen JS, Jakobsen E, Hølund B, Bertelsen K, Jakobsen A, Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer, Int J Gynecol Cancer, 2004, DOI: https://doi.org/10.1111/j.1048-891X.2004.14606.x
Brustmann H, Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome
Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN, Butzow R, Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma.
Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancerF R Hirsch, M Varella-Garcia and F Cappuzzo
M. M. Moasser, “The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis,” Oncogene,
D. J. Riese and D. F. Stern, “Specificity within the EGF family/ErbB receptor family signaling network,” BioEssays, vol. 20, pp. 41–48, 1998 DOI: https://doi.org/10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V
de Graeff P, Crijns AP, Ten Hoor KA, et al (2008).The ErbB signalling pathway; protein expression and prognostic value in epithelial ovarian cancer. DOI: https://doi.org/10.1038/sj.bjc.6604471
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
